Chief Executive Officer
Mr. Kunimoto brings more than 25 years of experience successfully leading agricultural biotechnology and biopharmaceutical companies. Previously, he served as a Partner and Chief Business Officer of Flagship Pioneering, a leading venture capital firm headquartered in Cambridge, Massachusetts. There he provided strategy and business development support to Flagship VentureLabs companies.
Prior to joining Flagship, Mr. Kunimoto was Chief Business Officer of Sapphire Energy, where he was responsible for establishing corporate partnerships to lead Sapphire’s commercial development. He was previously Senior Vice President of Corporate Development at Pacific Biosciences and Vice President, Corporate Strategy for Monsanto. At Monsanto he was responsible for broadening Monsanto’s access to cutting-edge technologies through R&D collaborations, licensing agreements, and partnerships with venture capital firms specializing in life sciences investing.
Prior to Monsanto, Mr. Kunimoto served as President and CEO of two venture capital-backed biopharmaceutical companies, Galileo Pharmaceuticals and Epicyte Pharmaceuticals, and was Senior Vice President of Corporate Development at Exelixis, a publicly traded bio-pharmaceutical company developing small-molecule cancer therapeutics, with responsibility for business development, mergers and acquisitions and intellectual property. He joined Exelixis from Calgene, a publicly traded agricultural biotechnology company, where he most recently served as President and CEO prior to its acquisition by Monsanto.
He earned a B.S. in Mathematics from Stanford University.